Discounted for Pipeline Risk, Not Quality
ZEAL trades at a discount, but the market sees a pipeline bet, not a quality name. Volatility is extreme at 61.5%. For a biotech with -38% margin, every trial update moves the stock. One bad study result, and the rerating is brutal.
Published by AssetNext · 2026-06-13
| Date | Signal | Peer score | Drawdown | 21d vs sector |
|---|---|---|---|---|
| 2026-06-30 | Quality under pressure | 83 | -46.9% | -12.7% |
| 2026-06-26 | Quality under pressure | 82 | -47.8% | -15.2% |
Break down ZEAL.CO's structural position across all peer dimensions with the interactive app.